Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7322MR)

This product GTTS-WQ7322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4908MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ3276MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ8004MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ101MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ13011MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ15094MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ7918MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ7733MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GLP-1Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW